References:
  1. Based on the results of Chapple C.R. et al. Tamsulosin, the First Prostate-Selective a1A-Adrenoceptor Antagonist. A Meta-Analysis of Two Randomized, Placebo-controlled,multicentre Studies in patients with Benign Prostatic Obstruction (Symptomatic BPH) Eur Urol 1996;29:155-167.

  2. Tamsulosin, A Selective a1A-adrenoceptor Antagonist: A Randomized, Controlled Trial in Patients with Benign Prostatic "Obstruction" (Symptomatic BPH). Abrams P.et al, and the European Tamsulosin Study Group. Br J Urol 1995;76(3):325-336.

  3. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Lepor H. Urology 1998;51(6):901-906.

  4. Group Members of United States 93 01 Study. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. Narayan P, Tewari A, J Urol 1998;160(5):1701-1706.

  5. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
    Narayan P, Lepor H. Urology 2001;57(3):466-470.

  6. FDA file for Alfuzosin www.fda.gov/cder/approval

  7. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM et al. Br J Urol 1997;80(4):597-605

  8. Tamsulosin: Real life clinical experience in 19,365 patients. Michel MC, Bressel HV. Mehlburgerl, et al, Eur Urol 1998;34 (supp. 2) 37-45.

  9. How are lower urinary tract symptoms managed in real life practice? The French experience. Vallahcieh G. Eur Urol 2000;38 (supp. 1) 54-59.

  10. alpha(1)-blockers for BPH: are there differences?
    Drugs of today. Schwihh DA. 2001;37 (supp. D) 13-16. Mey c.Eur Urol 1999; 36(supp 3):52-63

  11. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia.
    Drugs 1996;52(6):883-898. Wilde ML et al.

  12. Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.
    Chapple CR et al. Br J of Urol 1998;81(supp. 1)34-37. Foglar R et al. Eur J of Pharmacol 1995;288:201-207.

  13. The use of Ultrasound Estimated Bladder Weight (UEBW) in Evaluation of Change in Bladder Hypertrophy during Treatment with an a1 blocker. Sirone D et al. Eur Urol 2000;37(suppl 2):103.

  14. a-Blockers and Lower Urinary Tract function: More than Smooth Muscle Relaxation? Michel MC et al In press
    Br J Urol 2000, September.

  15. Tamsulosin 0.4 mg Once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Hofner K. Eur Urol 1999;36:335-41.

  16. Cialis SmPC

  17. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. Robert A Kloner, et al. J Urol 2004;(172)1935-1940.